Videos

Lucia Masarova, MD, PhD, discusses therapeutic options for patients with polycythemia vera who are refractory to hydroxyurea.

A closer look at disease modifying treatments in MDS, providing insights into their mechanisms of action and impact on the management of the disease.

Panelists provide insight on ongoing studies evaluating doublet combinations in frontline advanced RCC.

Expert oncolgists examine 1-year follow-up data from the IMerge trial, discussing the durability of response (transfusion independence), the impact of imetelstat on hemoglobin levels, key safety outcomes and managing cytopenias.

Experts share their approach to CEACAM5 testing, including the testing procedure, patient selection criteria, and timing of testing.

Expert oncologists share experiences and insights on key treatment protocols for patients with aRCC, including perspectives from community oncologists.

The role of CEACAM5, its expression in NSCLC, and its potential as a therapeutic target are thoroughly examined, including its impact on tumorigenesis and prognosis in NSCLC patients.

Christina Fotopoulou, MD, PhD, discusses the results of the DUO-O trial in patients with newly diagnosed ovarian cancer.

Sara Tolaney, MD, MPH, discusses sacituzumab govitecan-hziy as an effective and safe treatment for patients with hormone receptor-positive/HER2-negative metastatic breast cancer.

John Diaz, MD, discusses potential innovations for the ovarian cancer space.

Roby Thomas, MD, discusses the shortage of lutetium Lu 177 vipivotide tetraxetan, and how it had affected patients with metastatic castration-resistant prostate cancer being treated at UPMC Hillman Cancer Center.

Jonathan W. Goldman, MD, discusses the use of osimertinib in the first line setting for patients with non–small cell lung cancer.

Mitchell E. Horwitz, MD, discusses the next steps for research following the FDA approval of omidubicel.

Roby Thomas, MD discusses chemotherapy shortages and the impact these shortages have had on oncology research.

The panel shares future areas of research in malignant PEComa that interest them, and how they see the treatment landscape evolving.

Dr Andrew Wagner presents the case of a young man with a retroperitoneal PEComa.

Ashwin Kishtagari, MD, discusses the adverse events of pacritinib for patients with primary myelofibrosis and low platelet counts.

Amer Zeidan, MBBS, closes his discussion with a look at the potential implications of the COMMANDS trial data on the treatment of lower-risk MDS in clinical practice.

Dr Amer Zeidan details the design, patient population, and key efficacy and safety data from the phase 3 COMMANDS trial investigating luspatercept for the frontline treatment of lower-risk MDS with anemia.

Amer Zeidan, MBBS, explains the treatment options for patients with lower-risk MDS prior to the approval of luspatercept.

The panel engages in a discussion on lenvatinib dosing in clinical practice, addressing dose reductions, their impact on treatment effectiveness, and real-world tolerability.

Panelists analyze the 4-year follow-up results of the CLEAR study, covering study design, efficacy, safety, and clinical implications.

Dr Amy Dezern reviews the mechanism of action of luspatercept and its rationale for use in MDS.

Corey Cutler details the NIH Clinical Scoring of Organ System for chronic GHVD symptoms.

Amy Dezern, MD, MHS, details her experience with using erythropoiesis stimulating agents for the treatment of MDS in her clinical practice.

Colleen Danielson, NP, walks through how chronic GVHD symptoms are assessed.

Bradley J. Monk, MD, FACS, FACOG, discusses findings from the phase 3 KEYNOTE-826 trial of the addition of pembrolizumab to chemotherapy for patients with persistent, recurrent, or metastatic cervical cancer.

The discussion centered around emergent biomarkers and targeted therapies in NSCLC, exploring targets like CEACAM5, TROP2, HER3, cMET, and the potential role of antibody drug conjugates in refractory disease.

A comprehensive overview of the current landscape of non-small cell lung cancer (NSCLC), highlighting the impact of biomarkers on treatment selection.

An overview of the patient population and study design of the IMerge trial evaluating imetelstat, highlighting its MOA and rationale for its use in MDS, and reviews key efficacy outcomes, including HgB levels and transfusion independence.